Literature DB >> 28459181

Effect of Negative Pressure Wound Therapy on Cellular Fibronectin and Transforming Growth Factor-β1 Expression in Diabetic Foot Wounds.

Shao Ling Yang1,2, Lv Yun Zhu2, Rui Han3, Lei Lei Sun4, Jing Tao Dou1.   

Abstract

BACKGROUND: Chronic diabetic foot wounds are a leading cause of amputation, morbidity, and hospitalization for patients with diabetes. Negative-pressure wound therapy (NPWT) can putatively facilitate wound healing, but the underlying mechanisms remain unclear. Cellular fibronectin (cFN) and transforming growth factor-β1 (TGF-β1) play an important role in wound healing. This prospective randomized controlled trial evaluated the effects of NPWT on the production of cFN and the expression of TGF-β1 in diabetic foot wounds of patients.
METHODS: From January 2012 to January 2015, 40 patients with diabetic foot wounds were randomly and equally apportioned to receive either NPWT or advanced moist wound therapy (control) for 7 days. Granulation tissue was harvested before and after treatment. Immunohistochemistry and Western blot were performed to evaluate protein levels of cFN and TGF-β1, and real-time polymerase chain reaction (PCR) to measure corresponding mRNA expressions.
RESULTS: NPWT facilitated the expression of cFN and TGF-β1 in diabetic foot wounds. Immunohistochemical analysis revealed higher levels of cFN and TGF-β1 in the NPWT group than in the control group. Western blot and real-time PCR analysis further showed that protein and mRNA levels of cFN or TGF-β1 were higher in the NPWT group than that in the control group ( P < .01, both).
CONCLUSION: Our results showed that NPWT facilitated the production of cFN and the expression of TGF-β1 in granulation tissue in diabetic foot ulcers. LEVEL OF EVIDENCE: Level I, randomized controlled study.

Entities:  

Keywords:  cellular fibronectin; diabetic foot wounds; negative-pressure wound therapy; transforming growth factor-β1

Mesh:

Substances:

Year:  2017        PMID: 28459181     DOI: 10.1177/1071100717704940

Source DB:  PubMed          Journal:  Foot Ankle Int        ISSN: 1071-1007            Impact factor:   2.827


  6 in total

1.  Negative pressure wound therapy for treating foot wounds in people with diabetes mellitus.

Authors:  Zhenmi Liu; Jo C Dumville; Robert J Hinchliffe; Nicky Cullum; Fran Game; Nikki Stubbs; Michael Sweeting; Frank Peinemann
Journal:  Cochrane Database Syst Rev       Date:  2018-10-17

Review 2.  Role of TGF-β in Skin Chronic Wounds: A Keratinocyte Perspective.

Authors:  Sergio Liarte; Ángel Bernabé-García; Francisco J Nicolás
Journal:  Cells       Date:  2020-01-28       Impact factor: 6.600

3.  A pulsatile release platform based on photo-induced imine-crosslinking hydrogel promotes scarless wound healing.

Authors:  Jian Zhang; Yongjun Zheng; Jimmy Lee; Jieyu Hua; Shilong Li; Ananth Panchamukhi; Jiping Yue; Xuewen Gou; Zhaofan Xia; Linyong Zhu; Xiaoyang Wu
Journal:  Nat Commun       Date:  2021-03-15       Impact factor: 14.919

4.  Comparison of negative pressure wound therapy and moist wound care in patients with diabetic foot ulcers: A protocol for systematic review and meta-analysis of randomized controlled trials.

Authors:  Nan Wang; Shuang-Shuang Li; Ya-Ping Liu; Ying-Ying Peng; Peng-Fei Wang
Journal:  Medicine (Baltimore)       Date:  2022-08-05       Impact factor: 1.817

5.  HDAC5-mediated Smad7 silencing through MEF2A is critical for fibroblast activation and hypertrophic scar formation.

Authors:  Ya Gao; Yangdan Liu; Danning Zheng; Chiakang Ho; Dongsheng Wen; Jiaming Sun; Lu Huang; Yuxin Liu; Qingfeng Li; Yifan Zhang
Journal:  Int J Biol Sci       Date:  2022-09-11       Impact factor: 10.750

6.  Negative pressure wound therapy in the treatment of diabetic foot ulcers may be mediated through differential gene expression.

Authors:  S Borys; A H Ludwig-Slomczynska; M Seweryn; J Hohendorff; T Koblik; J Machlowska; B Kiec-Wilk; P Wolkow; Maciej T Malecki
Journal:  Acta Diabetol       Date:  2018-09-17       Impact factor: 4.280

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.